




IFW  
PATENT  
Attorney Docket No.: PP022717.0004

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First class mail with sufficient postage in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the below-identified date.

August 13, 2008  
Date

  
Kara Shure

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Angela Bardotti

Conf. No.: 6976

Serial No.: 10/593,005

Group Art Unit: Unassigned

371(c) Date: March 17, 2005

Examiner: Unassigned

For: ANALYSIS OF SACCHARIDE VACCINES WITHOUT INTERFERENCE

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on Form PTO/SB/08, submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

**This Information Disclosure Statement is being filed:**

within three months of the filing date of the patent application.

- within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- before** the mailing date of a first Office Action on the merits.
- after** the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
  - the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);  
**or**
  - the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
  - No fee is owed by the applicant(s).
- In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with  the first or  second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.
- after** the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), (see "Statement," and "Fees" below).
- Copies of each of the non-U.S. Patent documents listed on the attached Form PTO/SB/08, are enclosed herewith.

**EXCEPT THAT:**

- In view of the voluminous nature of reference @@, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith.

- In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached Form PTO/SB/08 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.
- If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

**Concise Explanation Requirement**

- The "concise explanation" requirement (non-English references) for reference B2 under 37 C.F.R. § 1.98(a)(3) is satisfied by:
  - the explanation provided on the attached sheet.
  - the explanation provided in the Specification.
  - submission of the enclosed International Search Report.
  - submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action..
  - the English-language abstract provided on the cover page of B2.

**Statement under 37 C.F.R. § 1.97(e)**

- The undersigned attorney hereby states that each item contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

**Fees**


- No Fee is owed by the applicant(s).

- The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.

**Method of Payment of Fees**

- Attached is a check in the amount of \$\_\_\_\_\_ This form is submitted in duplicate.
- Charge Deposit Account No. 03-1664 in the amount of \$180.00. This form is submitted in duplicate.
- Please charge any deficiency or credit any overpayment to Deposit Account 03-1664.
- No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,

  
Helen Lee  
Registration No. 39,270

Dated: August 13, 2008

NOVARTIS VACCINES AND DIAGNOSTICS, INC.  
Intellectual Property Dept. – X 100B  
4560 Horton Street  
Emeryville, CA 94608-2916  
Telephone: (510) 923-2192  
Facsimile: (510) 655-3542